ArticlesInsightsSubstance Compliance & Risk Mitigation Why Benzodiazepines and Amphetamines Must Be Treated Like Opioids Doug Jorgensen 9 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Addiction Recovery Treatment: Why It Belongs in the Same Risk Category as Opioid Prescribing Doug Jorgensen 8 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Frequency of Visits: A Key Factor in Controlled Substance Safety Doug Jorgensen 5 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Pill Counts: A Simple but Underused Compliance Tool Doug Jorgensen 6 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Prescription Monitoring Programs: How to Use Them Effectively Doug Jorgensen 7 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Urine Drug Testing: Best Practices for Compliance and Patient Safety Doug Jorgensen 6 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Controlled Substance Agreements: A Critical Tool for Risk Mitigation Doug Jorgensen 10 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation The Hidden Dangers of Benzodiazepines and Amphetamines in Primary Care and Psychiatry Doug Jorgensen 4 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Risk Mitigation Protocols: The Provider’s Best Defense Against Diversion and Government Overreach Doug Jorgensen 4 min read
ArticlesInsightsSubstance Compliance & Risk Mitigation Polypharmacy in Chronic Pain & Psychiatry: Why It’s Often the Only Way to Help Patients Function Doug Jorgensen 4 min read
